Clinical Advances in Hematology & OncologyPNH Management: A Clinical Case of Ravulizumab–Danicopan Combination Therapy

🎓 Expert Commentary / Peer Perspective

A 56-year-old woman with PNH achieved control of intravascular hemolysis on ravulizumab but remained anemic, with hemoglobin near 9.2 g/dL. After entering the ALPHA trial and adding danicopan, her hemoglobin increased to approximately 12 g/dL within three months. The case illustrates residual extravascular hemolysis during C5 inhibition and treatment-continuity challenges during international travel. Its single-patient observations require interpretation alongside randomized ALPHA trial findings, not as independent evidence of efficacy or protection during delayed dosing.

Clinical Considerations

• Persistent anemia during C5 inhibition may indicate extravascular hemolysis after alternative causes of anemia are evaluated.
• In ALPHA, danicopan add-on therapy produced a 2.44-g/dL treatment difference in hemoglobin change at week 12.
• Transfusion avoidance occurred in 83% with danicopan versus 38% with placebo during the randomized treatment period.
• The patient’s hemoglobin increased from approximately 9.2 to 12 g/dL, consistent with the treatment mechanism and trial population.
• Stability during a 10-week ravulizumab interval represents one patient’s experience and does not validate delayed terminal complement dosing.
• The author disclosed relationships with complement-inhibitor manufacturers, requiring awareness of potential promotional emphasis.

Practice Applications

• Evaluate persistent anemia, reticulocytosis, bilirubin, transfusion needs, and symptoms despite adequate control of intravascular hemolysis.
• Consider whether residual extravascular hemolysis explains an incomplete hematologic response during terminal complement inhibition.
• Monitor liver enzymes, hemolysis markers, hemoglobin, fatigue, transfusion requirements, and treatment adherence during combination therapy.
• Plan infusion access and contingency arrangements before international travel or other anticipated disruptions.
• Avoid interpreting this case as evidence that danicopan alone provides adequate protection during delayed ravulizumab administration.